1. |
Making progress against influenza |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
2. |
Return to more stringent control of MRSA needed in the UK? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
3. |
Management of chronic GVHD reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
4. |
Advice delivered by electronic mail on the use of antibacterials for catheter-related bloodstream infections can improve treatment |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
5. |
Two-in-one combo helps patients breathe easy, cut costs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
6. |
Adalimumab eases symptoms, economic burden of RA |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 7-8
L Hunt,
Preview
|
|
摘要:
Rheumatoid arthritis (RA) is a chronic, autoimmune disease that causes pain, swelling and stiffness in the joints of hands, feet and wrists, and can lead to the destruction of joints. Adalimumab [Humira; Abbott Laboratories] is the first fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody, and can be used as monotherapy or in combination with methotrexate or other disease-modifying antirheumatic drugs (DMARDs). Data presented at the 67th American College of Rheumatology (ACR) annual meeting [Orlando, Florida, US; October 2003] show that adalimumab provides long-term, clinically significant benefits, is well tolerated and is a cost-effective treatment alternative for patients with RA.1,2,3
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
7. |
Pemetrexed + folic acid in gastric cancer: activity, reduced toxicity |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
8. |
Cilomilast reduces airway inflammation in COPD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
9. |
DCF 987*appears to be effective and well tolerated in patients with cystic fibrosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
10. |
Ciclesonide: advantages over budesonide in asthma? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1415,
2003,
Page 11-12
RM Poole,
Preview
|
|
摘要:
Ciclesonide, a novel inhaled corticosteroid, is at least as effective as budesonide [Pulmicort Turbuhaler] in the treatment of asthma, according to the results of two 12-week studies presented at the 13th Annual Congress of the European Respiratory Society [Vienna, Austria; September-October 2003]. In the first study, a significantly greater mean improvement in pulmonary function was achieved in patients given ciclesonide, compared with those treated with budesonide. Furthermore, the onset of treatment benefit was earlier with ciclesonide, compared with budesonide, in this study. In the second study, once-daily treatment with ciclesonide produced increases in FEV1, forced vital capacity (FVC) and morning and evening peak expiratory flow (PEF) that were comparable to those achieved with twice-daily administration of budesonide. Two studies involving volunteers that were also presented at the meeting showed that the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl ciclesonide were different from those of budesonide.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|